![]() ![]() ![]() Utilizing the Ora-CAC®, the anti-allergic efficacy of DEXTENZA has been amply demonstrated. The current Ora-CAC®, accepted and implemented worldwide, has been validated through the real-world usage of its 20 approved anti-allergy products that have improved the quality of life of millions of allergy sufferers. ![]() “It is thrilling to see the intersection of Ocular Therapeutix’s innovative approach and Ora’s proven scientific precision advancing this important new treatment for patients with chronic allergy.”įor more information about the results of Ocular’s Phase 3 trial, which were announced on October 22, 2015, please visit the Ocular Therapeutix website at For three decades, Ora has been the leader in ocular allergy, both through environmental studies and through its various precise and reproducible models. DEXTENZA achieved 1-unit difference from vehicle in ocular itching, which has previously been the FDA standard for approval of therapies in this disease. Ora Inc., a global, full-service ophthalmic clinical research and product development firm, announced that its Conjunctival Allergen Challenge (Ora-CAC®) model recently confirmed Phase 2 clinical results of Sustained Release Dexamethasone (OTX-DP), a drug-eluting intracanalicular depot, under development by Ocular Therapeutix (Nasdaq: OCUL) as DEXTENZA, for the treatment of chronic allergic conjunctivitis. Ocular Therapeutix’s sustained release intracanalicular dexamethasone depot wins in Phase 3 development for treatment of chronic allergic conjunctivitis ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |